This is a very scientific entry at Cancer Consultants.com.  But if you want to research Myleodysplastic Syndromes, then here is some information.

Here’s the introduction:

The myelodysplastic syndromes (MDS) are a collection of clonally-derived hematopoietic disorders typified by peripheral blood cytopenias, transfusion-dependency, and in a subset of patients, increased likelihood of transformation to acute myeloid leukemia (AML).¹,² This past decade has brought increased attention to MDS with the approval by the U.S. Food and Drug Administration of three MDS therapies, and a more complete understanding of these diseases on a molecular level. This year at the American Society of Hematology (ASH) 2007 annual meeting, presentations focused on the implications and management of MDS- and treatment-related cytopenias; results of clinical trials of hypomethylating agents, including the first prospectively-acquired survival data; and extension of the potential applicability of immunomodulatory drugs.

Source:  CancerConsultants.com

Tags: "Myleodysplastic Syndromes" Treatment, Myleodysplastic Syndromes